PMID- 31593796
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 2213-7173 (Electronic)
IS  - 2213-7165 (Linking)
VI  - 21
DP  - 2020 Jun
TI  - Safety of longer linezolid regimen in children with drug-resistant tuberculosis 
      and extensive tuberculosis in Southwest China.
PG  - 375-379
LID - S2213-7165(19)30252-8 [pii]
LID - 10.1016/j.jgar.2019.09.019 [doi]
AB  - OBJECTIVES: Linezolid (LNZ) has recently been listed by the World Health 
      Organization (WHO) as a Group A agent for the treatment of multidrug-resistant 
      tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in 
      longer regimens (18-20 months). However, little is known about the safety of LNZ 
      in longer TB treatment regimens in children. METHODS: Here we report 31 children 
      who received LNZ treatment for drug-resistant tuberculosis (DR-TB) and extensive 
      tuberculosis in the Children's Hospital of Chongqing Medical University, China, 
      during September 2016 to March 2019. The mean duration of LNZ treatment was 8.56 
      months (range, 1-24 months). RESULTS: Of the 31 patients, 13 (42%) had suspected 
      or confirmed adverse events (AEs) related to LNZ treatment, including digestive 
      symptoms, haematological toxicity, neuropathy and lactic acidosis. Haematological 
      toxicity was the most frequent AE, presenting as leukopenia (9/13) and anaemia 
      (5/13). No hepatotoxicity or nephrotoxicity was observed. Two patients suffered 
      from life-threatening lactic acidosis when the LNZ dose was increased to 1.2 g 
      daily, however they recovered following LNZ withdrawal. CONCLUSION: A high rate 
      of AEs of LNZ treatment was observed in children receiving a longer regimen, 
      which might relate to the treatment course and dose. Haematological toxicity was 
      the most frequent AE in children. It is necessary to regularly monitor the blood 
      chemistry and lactic acid concentration during LNZ treatment.
CI  - Copyright (c) 2019 International Society for Antimicrobial Chemotherapy. Published 
      by Elsevier Ltd. All rights reserved.
FAU - Zhang, ZhenZhen
AU  - Zhang Z
AD  - Department of Infectious Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China; Ministry of Education Key Laboratory of Child 
      Development and Disorders, Key Laboratory of Pediatrics in Chongqing, Chongqing, 
      China.
FAU - Cheng, ZhenLi
AU  - Cheng Z
AD  - Department of Cardiology, Children's Hospital of Chongqing Medical University, 
      Chongqing, China.
FAU - Liu, QuanBo
AU  - Liu Q
AD  - Department of Infectious Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Shang, TingTing
AU  - Shang T
AD  - Department of Infectious Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Jiang, Li
AU  - Jiang L
AD  - Department of Infectious Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Fu, Zhou
AU  - Fu Z
AD  - Department of Respiratory Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Zhu, Kun
AU  - Zhu K
AD  - Department of Radiology, Children's Hospital of Chongqing Medical University, 
      Chongqing, China.
FAU - Wang, Xiao
AU  - Wang X
AD  - Department of Infectious Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Chen, Juan
AU  - Chen J
AD  - Department of Infectious Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China; The Key Laboratory of Molecular Biology of 
      Infectious Diseases Designated by the Chinese Ministry of Education, Chongqing, 
      China.
FAU - Xu, HongMei
AU  - Xu H
AD  - Department of Infectious Diseases, Children's Hospital of Chongqing Medical 
      University, Chongqing, China; Ministry of Education Key Laboratory of Child 
      Development and Disorders, Key Laboratory of Pediatrics in Chongqing, Chongqing, 
      China. Electronic address: xuhongm0095@cqmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191005
PL  - Netherlands
TA  - J Glob Antimicrob Resist
JT  - Journal of global antimicrobial resistance
JID - 101622459
RN  - 0 (Antitubercular Agents)
RN  - ISQ9I6J12J (Linezolid)
SB  - IM
MH  - Antitubercular Agents/adverse effects
MH  - Child
MH  - China
MH  - *Extensively Drug-Resistant Tuberculosis/drug therapy
MH  - Humans
MH  - Linezolid/adverse effects
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy
OTO - NOTNLM
OT  - Adverse event
OT  - Drug-resistant tuberculosis
OT  - Linezolid
OT  - Safety
EDAT- 2019/10/09 06:00
MHDA- 2021/06/24 06:00
CRDT- 2019/10/09 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2019/09/12 00:00 [revised]
PHST- 2019/09/27 00:00 [accepted]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2019/10/09 06:00 [entrez]
AID - S2213-7165(19)30252-8 [pii]
AID - 10.1016/j.jgar.2019.09.019 [doi]
PST - ppublish
SO  - J Glob Antimicrob Resist. 2020 Jun;21:375-379. doi: 10.1016/j.jgar.2019.09.019. 
      Epub 2019 Oct 5.